NASDAQ:IPHS - Innophos Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$49.26 +0.02 (+0.04 %)
(As of 07/16/2018 08:06 AM ET)
Previous Close$49.24
Today's Range$47.63 - $49.47
52-Week Range$38.66 - $51.34
Volume53,468 shs
Average Volume63,242 shs
Market Capitalization$962.59 million
P/E Ratio20.02
Dividend Yield3.90%
Innophos logoInnophos Holdings, Inc., together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste. It also provides food and technical grade purified phosphoric acid (PPA) used in the production of phosphate salts, as well as in food and beverages, and water treatment applications; technical grade sodium tripolyphosphate (STPP), a specialty phosphate, which is used as an ingredient in cleaning products, such as industrial and institutional cleaners, automatic dishwashing detergents, and consumer laundry detergents, as well as in water treatment, clay processing, and copper ore processing activities; and detergent grade PPA that is primarily used in the production of STPP. In addition, the company offers granular triple super-phosphate (GTSP), a fertilizer product line used for enhancing crop yields in various agricultural sectors; and merchant green phosphoric acid. It serves primarily consumer goods manufacturers, distributors, and specialty chemical manufacturers in the United States, Canada, Mexico, and internationally. Innophos Holdings, Inc. was founded in 2004 and is headquartered in Cranbury, New Jersey.

Receive IPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for IPHS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Chemicals & allied products
Sub-IndustrySpecialty Chemicals
SectorBasic Materials


Debt-to-Equity Ratio1.03
Current Ratio3.22
Quick Ratio1.70


Trailing P/E Ratio20.02
Forward P/E Ratio18.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$722.02 million
Price / Sales1.33
Cash Flow$4.5823 per share
Price / Cash10.75
Book Value$17.08 per share
Price / Book2.88


EPS (Most Recent Fiscal Year)$2.46
Net Income$22.44 million
Net Margins2.95%
Return on Equity14.26%
Return on Assets6.54%


Outstanding Shares19,540,000
Market Cap$962.59

The Truth About Cryptocurrencies

Innophos (NASDAQ:IPHS) Frequently Asked Questions

What is Innophos' stock symbol?

Innophos trades on the NASDAQ under the ticker symbol "IPHS."

How often does Innophos pay dividends? What is the dividend yield for Innophos?

Innophos announced a quarterly dividend on Wednesday, May 2nd. Shareholders of record on Friday, May 18th will be paid a dividend of $0.48 per share on Tuesday, June 5th. This represents a $1.92 annualized dividend and a yield of 3.90%. The ex-dividend date is Thursday, May 17th. View Innophos' Dividend History.

How were Innophos' earnings last quarter?

Innophos Holdings, Inc. (NASDAQ:IPHS) issued its quarterly earnings results on Tuesday, May, 1st. The specialty chemicals company reported $0.61 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.06. The specialty chemicals company had revenue of $205 million for the quarter, compared to the consensus estimate of $196.91 million. Innophos had a return on equity of 14.26% and a net margin of 2.95%. The firm's revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.59 EPS. View Innophos' Earnings History.

What guidance has Innophos issued on next quarter's earnings?

Innophos updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $2.71-$2.80 for the period, compared to the Thomson Reuters consensus estimate of $2.74. The company issued revenue guidance of $808.6-$823.1 million, compared to the consensus revenue estimate of $814.50 million.

What is the consensus analysts' recommendation for Innophos?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innophos in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Innophos' key competitors?

Who are Innophos' key executives?

Innophos' management team includes the folowing people:
  • Dr. Kim Ann Mink, Chairman, CEO & Pres (Age 58)
  • Mr. Hermanus Kieftenbeld, Sr. VP & CFO (Age 52)
  • Ms. Sherry Duff, Sr. VP and Chief Marketing & Technology Officer (Age 50)
  • Mr. Joshua Horenstein, Sr. VP, Chief Legal Officer & Corp. Sec. (Age 41)
  • Ms. Amy Hartzell, Sr. VP of Supply Chain & Purchasing (Age 42)

Has Innophos been receiving favorable news coverage?

Media coverage about IPHS stock has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Innophos earned a news impact score of 0.15 on Accern's scale. They also assigned media stories about the specialty chemicals company an impact score of 46.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Innophos' major shareholders?

Innophos' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Confluence Investment Management LLC (0.54%) and Dalton Greiner Hartman Maher & Co. (0.38%). View Institutional Ownership Trends for Innophos.

Which major investors are buying Innophos stock?

IPHS stock was purchased by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co. and Confluence Investment Management LLC. View Insider Buying and Selling for Innophos.

How do I buy shares of Innophos?

Shares of IPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innophos' stock price today?

One share of IPHS stock can currently be purchased for approximately $49.26.

How big of a company is Innophos?

Innophos has a market capitalization of $962.59 million and generates $722.02 million in revenue each year. The specialty chemicals company earns $22.44 million in net income (profit) each year or $2.46 on an earnings per share basis. Innophos employs 1,373 workers across the globe.

How can I contact Innophos?

Innophos' mailing address is 259 PROSPECT PLAINS ROAD, CRANBURY NJ, 08512. The specialty chemicals company can be reached via phone at 609-495-2495 or via email at [email protected]

MarketBeat Community Rating for Innophos (NASDAQ IPHS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  262 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  497
MarketBeat's community ratings are surveys of what our community members think about Innophos and other stocks. Vote "Outperform" if you believe IPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.